Compare NBN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | CERT |
|---|---|---|
| Founded | 1872 | 2008 |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | NBN | CERT |
|---|---|---|
| Price | $130.50 | $8.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $130.50 | $11.67 |
| AVG Volume (30 Days) | 99.6K | ★ 3.9M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $13.77 | $4.18 |
| Revenue Next Year | $18.72 | $5.39 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $80.75 | $4.45 |
| 52 Week High | $142.31 | $13.88 |
| Indicator | NBN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 63.31 |
| Support Level | $127.84 | $7.94 |
| Resistance Level | $137.75 | $9.93 |
| Average True Range (ATR) | 2.97 | 0.37 |
| MACD | -0.49 | -0.01 |
| Stochastic Oscillator | 23.82 | 83.04 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.